Publications

Add filters (0)

925 results

Accelerated basement membrane remodeling and serum matrix fragments as biomarkers of fibrosis in Alport syndrome.

May 26, 2026

Cell Rep

Abstract Chronic kidney disease (CKD) is characterized by fibrosis. Alport syndrome, a common monogenic form of CKD caused by collagen type IV variants, leads to basement membrane defects and progressive fibrosis. Understanding extracellular matrix dynamics is crucial for identifying disease-specific biomarkers and optimizing therapeutic timing. We applied a discovery approach combining stable C-lysine metabolic labeling […]

Read publication

Serum Markers of Fibroinflammatory Activity PRO-C3 and CPa9-HNE Are Associated with Liver-Related Outcomes in Patients with Chronic Hepatitis C.

May 15, 2026

J Infect Dis

Abstract BACKGROUND Chronic hepatitis C (CHC) infection remains a global health burden, contributing to the risk of long-term complications such as progressive fibrosis, cirrhosis, and hepatocellular carcinoma, particularly in undiagnosed or untreated individuals. Novel biomarkers for the assessment of disease progression and prognosis are required for fibroinflammatory chronic liver disease. Our study population from the […]

Read publication

Paired Liver Biopsies vs Noninvasive Tests as Surrogate Endpoints for Clinical Trials in Metabolic and Alcohol-Related Liver Disease and Alcohol-Related Liver Disease.

May 14, 2026

Clin Gastroenterol Hepatol

Abstract BACKGROUND & AIMS Drug development for metabolic and alcohol-related liver disease and alcohol-related liver disease is emerging, but designing clinical trials remains challenging due to unknown disease progression rates and a lack of validated surrogate endpoints. We studied fibrosis progression rates and determinants of progression using dual liver biopsies and compared the prognostic performance […]

Read publication

Longitudinal Circulating Procollagen-markers PRO-C1 and PRO-C2 Reflect Pubertal Growth Spurt in Healthy Adolescents.

May 13, 2026

J Clin Endocrinol Metab

Abstract INTRODUCTION Epiphyseal growth plate development is stimulated by GH and IGF-I. Serum IGF-I is applied as an efficacy and safety marker, monitoring growth in short GH-treated children. However, IGF-I offers poor guidance to clinicians, especially in children without GHD. Thus, novel biomarkers reflecting endogenous and GH-induced linear growth are needed. We evaluated the association […]

Read publication

Therapeutic subtypes of knee osteoarthritis: differential treatment effects among predicted endotypes in past clinical trials.

May 7, 2026

Arthritis Res Ther

Abstract BACKGROUND Molecular endotyping may facilitate the successful development of personalized treatments of knee osteoarthritis (KOA). The aim of this exploratory and hypothesis-generating study was to develop a clinically actionable tool for predicting molecular endotypes of KOA using blood-based biomarkers, and to explore the potential for differential treatment effects across biomarker-based endotypes in prior phase […]

Read publication

Circulating Endotrophin Predicts Myocardial Fibrosis Burden and Is Sensitive to Antifibrotic Therapy.

May 1, 2026

JACC Adv

Abstract BACKGROUND Novel collagen-derived circulating peptides, such as endotrophin, have been proposed as biomarkers of myocardial fibrosis. OBJECTIVES We aimed to determine the effect of pirfenidone, an antifibrotic agent, on circulating levels of these peptides, and their association with cardiovascular magnetic resonance extracellular volume (ECV). METHODS In the PIROUETTE (Pirfenidone in Patients with Heart Failure […]

Read publication

Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

May 1, 2026

Osteoporos Int

Abstract UNLABELLED The relationship between bone mineral density (BMD) at the femoral neck and fracture risk was determined in a meta-analysis of primary data of 307205 men and women from 53 cohort studies. Low BMD was an important predictor of fracture risk, particularly for hip fracture. INTRODUCTION This study aimed to quantify the relationship between […]

Read publication

Extracellular matrix deposition drives disease progression and reduces rapamycin response in lymphangioleiomyomatosis.

May 1, 2026

Eur Respir J

Abstract RATIONALE Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease driven by nodules containing “LAM cells” and recruited LAM-associated fibroblasts. Although rapamycin reduces lung function loss, some patients continue to decline, meaning additional therapies are needed. OBJECTIVES To investigate how the LAM nodule environment affects LAM cell proliferation and the response to rapamycin. METHODS Proteins […]

Read publication